Failure in the pathobiology of Alzheimer’s disease: new approach to therapy,” CNS and Neurological Problems Drug Targets, vol. 12, no. six, pp. 870?81, 2013. [17] E. Corsini, V. Galbiati, D. Nikitovic, and also a. M. Tsatsakis, “Role of oxidative anxiety in chemical allergens induced skin cells activation,” Food and Chemical NOTCH1 Protein Species Toxicology, vol. 61, pp. 74?1, 2013. [18] J. Li, H. Zhang, W. Huang, H. Qian, and Y. Li, “TNF-alpha inhibitors with anti-oxidative tension activity from natural solutions,” Present Subjects in Medicinal Chemistry, vol. 12, no. 13, pp. 1408?421, 2012. [19] L. Speranza, M. Pesce, A. Patruno et al., “Astaxanthin remedy decreased oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target,” Marine Drugs, vol. ten, no. four, pp. 890?99, 2012. [20] M. A. Montano, I. B. da Cruz, M. M. Duarte et al., “Inflammatory cytokines in vitro production are linked with Ala16Val superoxide dismutase gene,” Cytokine, vol. 60, no. 1, pp. 30?three, 2012. [21] X. Y. Zhang and J. K. Yao, “Oxidative pressure and therapeutic implications in psychiatric disorders,” Progress in NeuroPsychopharmacology and Biological Psychiatry, vol. 46, pp. 197?199, 2013. [22] S. Rowley and M. Patel, “Mitochondrial involvement and oxidative tension in temporal lobe epilepsy,” Absolutely free Radical Biology and Medicine, vol. 62, pp. 121?31, 2013. [23] B. Menon, K. Ramalingam, and R. V. Kumar, “Oxidative strain in patients with epilepsy is independent of antiepileptic drugs,” Seizure, vol. 21, no. ten, pp. 780?84. [24] B. N. Frey, A. C. Andreazza, J. Houenou et al., “Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Issues Biomarkers Task Force,” AustralianEthical ApprovalThe study was authorized by the local Ethics Committee on the Health-related Faculty on the University of Leipzig (no. 351-1013122010).Conflict of InterestsProfessor H. Himmerich received speaker honorarium from AstraZeneca, Lilly, and Servier; consulting costs from BristolMyers Squibb; and chemical substances for study assistance from Lundbeck, AstraZeneca, Novartis, and Wyeth. All other authors reported no biomedical financial interests or prospective conflict of interests.Author’s ContributionH. Himmerich and S. Bartsch contributed equally for the paper.AcknowledgmentThe study was supported by the Claussen-Simon Foundation. The mentioned sponsor did not have any influence on study design, collection, evaluation, and interpretation of information; writing of your report; or the decision to submit the paper for publication.
Mar. Drugs 2013, 11, 4279-4293; doi:10.3390/mdOPEN ACCESSmarine drugsISSN 1660-3397 mdpi/journal/marinedrugs ArticleEfficient Screening of Marine Extracts for Protease Inhibitors by Combining FRET Primarily based Activity Assays and Surface Plasmon Resonance Spectroscopy Primarily based Binding AssaysTony Christopeit 1,2,, Carboxypeptidase B2/CPB2, Human (HEK293, His) kersti erb?, U. Helena Danielson 2 and Inge W. Nilsennofima AS, Muninbakken 9-13, Troms?291, Norway; E-Mails: [email protected] (K.?); [email protected] (I.W.N.) Division of Chemistry–BMC, Uppsala University, Box 576, Uppsala 751 23, Sweden; E-Mail: [email protected] Author to whom correspondence need to be addressed; E-Mail: [email protected]; Tel.: +47-77-62-9234. Received: 3 July 2013; in revised type: 20 October 2013 / Accepted: 21 October 2013 / Published: 30 OctoberAbstract: The screening of extracts from marine organisms is really a broadly applied approach to learn new drug leads. A prevalent dilemma inside the scre.